Somatostatin (ST) inhibits gastrointestinal motility and exocrine and endo crine secretions. In animals, ST has been demonstated to decrease food intake. We investigated, in a randomized double-blind investigation in 10 healthy humans, the effects of an intravenous ST infusion compared to saline on sub jective hunger feelings. After 1 h, a low dose of fat was given intraduodenally to induce the release of endogenous upper-intestinal satiety factors. Ninety minutes later sandwiches were served and eaten until satiation. In the first hour, when no intraduodenal fat was given, there was a significant decrease in feelings of hunger with ST (p < 0.05). During the intraduodenal fat infusion this pattern reversed with a trend towards less satiety with ST. Food intake during intraduodenal fat infusion tended to be higher during ST (305 ± 42 g) than during saline (205 ± 36 g) although not significantly. In the 5 h after the experiment hunger feelings were significantly less after ST. In conclusion, we found evidence for a satiety effect of ST in humans which reversed towards less satiety when intraduodenal intralipid, which presumably produced endog enous satiety factors, was given. Postmeal satiety is higher after ST.
Introduction
Somatostatin is a cyclic tetradecapeptide with a distri bution throughout the nervous system, the gastrointesti nal tract, and other parts of the body [1]. Among its actions are the inhibition of the release of several gastroin testinal peptides including gastrin [2], secretin [3] , vasoac tive intestinal polypeptide [4] , cholecystokinin [5] , and motilin [6] , as well as insulin [7, 8] and glucagon [7] , In addition, somatostatin has been demonstrated to affect end-organ responses to selected stimuli in several animal species. For example, direct inhibition of human parietal cell secretion of acid [9, 10] , pancreatic acinar cell secre tion of enzymes [11] , (3-cell secretion of insulin [7] , and primate resting lower esophageal sphincter pressure [ 12] have been reported. Furthermore, it has been demon strated that exogenous ST inhibits motility functions in the human gastrointestinal tract [13] . In animals ST has been demonstrated to decrease food intake [14] [15] [16] , In the present study, we wanted to investigate the satie ty effects of ST in humans, basally, during low-dose intra duodenal intralipid infusion which may induce release of gastrointestinal hormones without disturbing gastrointes tinal motility, and postprandially.
Subjects and Methods
Ten healthy volunteers (5 M, 5 F, mean age 26) participated in this double-blind, randomized study. Informed consent was obtained from all subjects. The study was approved by the local ethics commit tee of the University of Leiden.
For every experiment each subject presented, after an overnight fast, at 8 a.m. at our research unit where a PVC Freka tube CH8 was introduced through one of the nostrils into the duodenum using a guide wire. After correct positioning as ascertained by fluoroscopy the guide wire was removed and the tube fixed to the nose. The fol lowing hour the volunteers accustomed to the intraduodenal tube and at 9 a.m. an intravenous catheter was placed into each forearm.
From one catheter blood was drawn from 9. [14] (UCB, Brussels, Belgium, 125 (ig/h after a loading dose of 125 |xg) was started. This dose was given because we and oth ers previously found that higher doses increased abdominal discom fort and nausea [13] . At t = 60 min the intraduodenal infusion of intralipid 20% (KabiVitrum®) 30 ml/h was started. From t = 60 min until the end of the infusion at t = 210 min 15 g intralipid was infused into the duodenum.
At noon (t = 150 min) identical sandwiches with 10 g margarine and 15 g cheese (3.33 kcal/g) were served and the volunteers were invited to eat until they were fully satiated. The amount eaten was carefully determined as was the duration of the meal. They were allowed to drink mineral water (without carbon dioxide) as wanted.
Basally and every 15 min hunger feelings, fullness feelings, pro spective feeding intentions and wish to eat were scored as hunger parameters on 100-mm visual analogue scales as described by Blun dell and Burley [17] and Silverstone [18] .
The subjects were also asked to fill in these hunger scores at home after the experiment at 2,3,4,5 and 6 p.m. to assess satiety.
As described by Hill [19] and modified to Dutch feeding customs, every 30 min from t = 0 min to t = 210 min, a list and photograph of 6 protein-rich, 6 fat-rich, 6 carbohydrate-rich items (the amount of each item on the photograph containing 200 kcal) and 6 low-energy items were presented. From each of these 24 items the subjects were asked if they wanted to eat the amount shown, double the amount, half the amount or nothing independent of the other items. At each time interval the total amount of caloric items was calculated (half the amount = % caloric item, double the amount is 2 caloric items). Also, the amount of protein, fat and carbohydrate items that the sub jects wanted to eat was calculated independently. Plasma CCK was determined in one run using a sensitive and specific radioimmunoas say as has previously been described. The intra-assay variation was between 4.6 and 11.5% [20] .
Results are expressed as means ± SEM. Statistical analysis of hunger feelings was performed by calculating the integrated area under the curve followed by Wilcoxon's test for paired results. These nonparametric tests were also used for the other comparisons.
Results
During the first 60 min, when no intraduodenal fat was given there was a significant decrease in hunger during ST infusion compared to saline (p < 0.05). The same trend was seen for the other hunger parameters ( fig. 1, 2) .
During the intraduodenal fat infusion this pattern reversed with a trend towards less satiety with ST ( fig. 1,2 ). There were no significant differences for the protein, fatty or carbohydrate-rich items. Food intake during the intraduodenal fat infusion was higher during ST (305 ± 42 g) than during saline (205 ± 36 g) although not significantly.
In the 5 h after the experiment, feelings for hunger, wish to eat and prospective feeding were significantly less after ST (p < 0.05) (fig. 3 ).
Mean basal plasma CCK was comparable in the saline (2.6 ± 0.1 pM ) and ST experiment (2.9 ± 0.4 pM). In the first 60 min of the intravenous infusion ST induced a sig nificant decrease in plasma CCK to 1.9 ± 0.2 pM (p < 0.01). During the intraduodenal fat infusion plasma CCK did not change anymore (fig. 4) . In the saline experiment there was a significant increase in plasma CCK during the intraduodenal fat infusion to 4.8 ± 0 .4 pM at t = 150 min (p < 0.001).
During the experiments no adverse effects were re corded, but 3 of the 10 subjects reported nausea in the afternoon after ST infusion.
Discussion
This study indicates that ST may also induce satiety in humans. We hypothesize that the reversal towards less satiety with ST compared to saline after the intraduodenal intralipid infusion may be explained by inhibition of endogenous satiety factors by ST.
In the first hour, when no intraduodenal fat was given, there was a trend to more satiety with ST for all parame ters tested which reached significance for the hunger feel ings (p < 0.05). During the low-dose intraduodenal fat infusion, which presumably induced the release of endog enous satiety factors, this pattern reversed with a trend (most clearly in the last 15 min) towards less satiety dur ing ST and also food intake thereafter was nearly 50% higher during ST.
Cholecystokinin (CCK) may be an important endoge nous satiety factor. In many studies in animals and humans it has been demonstrated that CCK decreases food intake [21] [22] [23] [24] [25] . We have shown that ST prevents the release of CCK during low-dose intraduodenal intralipid infusion. ST also prevents the release of other hormones, some of which may have satiety effects [ 1 ]. We hypothe size that the inhibition of the release of endogenous satie ty factor during low-dose intraduodenal fat infusion is the mechanism whereby ST may decrease satiety and in crease food intake in that period.
In animals ST has been demonstrated to decrease food intake [14, 15] . We have now shown that ST may also have satiety effects in humans, because hunger feelings were significantly less with ST in the first hour of our experiments and in the hours after the experiment. The mechanism whereby ST induces satiety may involve effects on gastrointestinal motility, gastrointestinal hor mones or a direct effect of ST as a neurotransmitter or a satiety agent. It is also possible that ST acts by direct stim- [26] . STs universal reduced feeding by a vagally mediated mechanism and that inhibitory effect is believed to be due to intracellular this decrease in food intake is not due to illness or malaise * dephosphorylation of cellular proteins by phosphatases [14] [15] [16] . This is rather similar to the satiety effects of CCK [26] . The final step in somatostatin action appears to be which are also mediated through the vagus nerve [ 15] . its ability to inhibit gene expression [26] In conclusion, we found evidence for a satiety effect of It has been demonstrated that the long-acting somato-ST which reversed towards less satiety when a low7 dose of statin analogue sandostatin (SMS) induces a threefold intraduodenal fat, which presumably induced endogeprolongation of mouth to cecum transit time [27, 28] and nous satiety factors, was given. Postmeal satiety is higher also ST dose-dependently prolonged intestinal transit after ST.
